Benchmark Co. Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $8
Analysts Offer Insights on Healthcare Companies: Illumina (ILMN) and OmniAb (OABI)
OmniAb Analyst Ratings
RBC Capital Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $7
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Avadel Pharmaceuticals (AVDL) and Regulus (RGLS)
OmniAb Analyst Ratings
HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
RBC Capital Keeps Their Buy Rating on OmniAb (OABI)
Buy Rating Affirmed for OmniAb Amid Solid Financials and Promising Growth Prospects
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating
Craig-Hallum Sticks to Its Buy Rating for OmniAb (OABI)
Craig-Hallum Reaffirms Their Buy Rating on OmniAb (OABI)
OmniAb Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Legend Biotech (LEGN), Green Thumb Industries (OtherGTBIF) and OmniAb (OABI)
RBC Capital Reaffirms Their Buy Rating on OmniAb (OABI)
Analysts Offer Insights on Healthcare Companies: ALX Oncology Holdings (ALXO), Lantern Pharma (LTRN) and OmniAb (OABI)
OmniAb (OABI) Receives a Buy From Craig-Hallum
RBC Capital Remains a Buy on OmniAb (OABI)
RBC Capital Remains a Buy on OmniAb (OABI)
No Data
No Data